The rationale for targeting TGF-β in chronic liver diseases

Author:

Giannelli Gianluigi1ORCID,Mikulits Wolfgang2,Dooley Steven3,Fabregat Isabel4,Moustakas Aristidis5,ten Dijke Peter6,Portincasa Piero1,Winter Peter7,Janssen Richard8,Leporatti Stefano9,Herrera Blanca10,Sanchez Aranzazu10

Affiliation:

1. Department of Biomedical Sciences and Human Oncology; University of Bari Medical School; Bari Italy

2. Department of Medicine I; Institute of Cancer Research; Comprehensive Cancer Center; Medical University of Vienna; Vienna Austria

3. Department of Medicine II; Medical Faculty; Mannheim Heidelberg University; Heidelberg Germany

4. Bellvitge Biomedical Research Institute (IDIBELL); L'Hospitalet; Barcelona Spain

5. Department of Medical Biochemistry and Microbiology and Ludwig Institute for Cancer Research; Biomedical Center; Uppsala University; Uppsala Sweden

6. Department of Molecular Cell Biology; Cancer Genomics Centre Netherlands; Leiden University Medical Center; Leiden the Netherlands

7. GenXPro GmbH; Frankfurt Germany

8. Galapagos; Leiden the Netherlands

9. CNR NANOTEC - Institute of Nanotechnology; Lecce Italy

10. Dep. Bioquímica y Biología Molecular II; Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC); Universidad Complutense; Madrid Spain

Funder

EU-Marie Curie Initial Training Network (ITN)

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3